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ABSTRACT
Background. Breast-conserving surgery (BCS) is the
preferred treatment for nonpalpable breast carcinoma. The
outcome, however, may be disappointing. In this study
surgical outcome in a large cohort of patients diagnosed
with nonpalpable breast carcinoma is evaluated.
Methods. In 833 patients with 841 nonpalpable breast
carcinomas the number of re-excisions and type of surgical
procedures was calculated and summed per patient. Sub-
sequently, the number of conversions to mastectomy and
the number of days until complete tumor removal were
analyzed. In a subgroup analysis the patients with an in situ
carcinoma were compared with the patients with an inva-
sive carcinoma.
Results. The initial surgery consisted of BCS for 589
tumors (70%) and of mastectomy for 242 tumors (29%).
For ten tumors (1%) the initial surgery was unknown. After
BCS, 158/589 tumors (27%) required a re-excision: 116/
337 (34%) for the in situ carcinomas and 63/504 (13%) for
the invasive carcinomas (p = 0.0001). The number of
conversions from BCS to mastectomy was 106/589 (18%):
66/241 (28%) in patients diagnosed with an in situ carci-
noma versus 40/348 (11%) in patients with an invasive
carcinoma (p = 0.0001). The median number of days until
complete tumor removal was 28, being 38 days for the in
situ carcinomas and 25 days for the invasive carcinomas
(p = 0.0001).
Conclusions. There is room for improvement in the sur-
gical treatment of nonpalpable breast carcinoma, especially
the relatively favorable in situ carcinoma, as it requires
signiﬁcantly more excisions, mastectomies, conversions to
mastectomy, and days for complete removal.
The most radical change in breast surgery has been the
transition from modiﬁed radical mastectomy to breast-
conserving surgery (BCS), ﬁrst described in 1969.
1 Fol-
lowing several large randomized clinical trials that showed
no difference in long-term survival after BCS compared
with radical mastectomy, BCS in combination with radio-
therapy became the new standard of care for women with
early-stage breast carcinomas.
2–4 Another example of the
development towards a less-invasive approach of breast
cancer diagnosis and treatment was the replacement of
open breast biopsy by large core needle biopsy (LCNB).
The Core Needle Biopsy after Radiological Localization
(COBRA) study was conducted in 973 patients with
radiologically suspicious nonpalpable breast lesions to
assess whether the sensitivity and speciﬁcity of large core
needle biopsy were comparable to the diagnostic perfor-
mance of open breast biopsy.
5 The results of this study
showed a comparable diagnostic performance for large
core needle biopsy and open breast biopsy.
5,6 A second
study (COBRA2000) was performed to assess the diag-
nostic performance of the COBRA guidelines outside a
controlled study setting, i.e., in clinical practice.
7 In clini-
cal practice the sensitivity of LCNB of nonpalpable breast
lesions approached the high sensitivity of the surgical
excision biopsy.
8
The introduction of large breast cancer screening pro-
grams in most Western countries resulted in the detection
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carcinomas.
9 The increasing number of small, early-stage
breast cancer stimulated the development of less-invasive
diagnostic and treatment modalities. Early-stage, small
nonpalpable tumors are difﬁcult to discern at surgery.
Therefore a guide wire is usually placed preoperatively to
allow localization of the tumor. However, placement of the
hooked guide wire may be difﬁcult in patients with dense
breast tissue. The likelihood of wire displacement is
increased in these patients and repositioning of the wire in
dense ﬁbroglandular tissue is often problematic. Further-
more, surgical excision with tumor-free resection margins
is technically challenging even with a perfectly placed
wire.
10–12 The literature on surgical outcome purely
focusing on nonpalpable breast cancer is scarce and often
includes diagnostics excisions.
13
Overall, in patients with a nonpalpable breast tumor, a
re-excision is reported to be necessary in 40–56%.
14–17
The purpose of this study was to evaluate the number of
re-excisions and the number of conversions from BCS to
mastectomy in patients with a nonpalpable malignancy on
LCNB. Furthermore, the time interval between LCNB
diagnosis and complete removal of all tumorous tissue was
assessed.
MATERIALS AND METHODS
Patients
Patients were retrieved from the COBRA/COBRA2000
study, which was conducted from 1997 to 2003.
This cohort was described in detail by Hoorntje et al.
and Verkooijen et al.
5,18 A total of 1,700 consecutive
patients underwent LCNB. Inclusion criteria for this study
included a nonpalpable malignancy (in situ or invasive) on
LCNB and available histopathological data on both LCNB
and surgical specimens. Exclusion criteria were missing
pathology data until 1 year after biopsy and a benign
LCNB diagnosis. Ultimately 856 patients diagnosed with
an invasive or noninvasive carcinoma on LCNB were eli-
gible for inclusion.
Large Core Needle Biopsy
LCNB was performed following a standard protocol in
four medical centers.
5 Lesions were localized with digital
mammography. A minimum of ﬁve biopsy specimens was
taken. In case of microcalciﬁcations, at least eight speci-
mens were obtained and specimen radiography was carried
out to identify the calciﬁcations in the biopsy specimen.
After the LCNB, patients returned to the hospital that they
were referred from. There, all further diagnostic (including
histological analysis of the LCNB tissue samples) and
therapeutic procedures were performed in a routine clinical
setting. All patients with an in situ carcinoma or an inva-
sive carcinoma underwent a hooked wire localized surgical
excision.
Histopathological Analysis
Histopathological samples were taken from the macro-
scopically closest margin. Tumor free margins of[1m m
were considered adequate. Tumor tissue in B2 low-power
ﬁelds (LPF) was considered focal irradicality and treated
with local radiotherapy. Irradicality was deﬁned as tumor
tissue in[2 LPF and was treated with a re-excision or
mastectomy.
Data Collection and Analysis
To avoid missing surgical procedures the number and
type of surgical procedures, histopathological diagnosis,
and time between the LCNB diagnosis and ﬁnal surgery up
to a maximum of 1 year after initial LCNB were extracted
from the Dutch National Pathology Database (Pathologisch
Anatomisch Landelijk Geautomatiseerd Archief, PALGA).
The ﬁrst surgical procedure after LCNB was assessed,
the number of initial planned mastectomies and the number
of surgical procedures for complete tumor removal were
calculated and summed per patient, and the number of
conversions from BCS to mastectomy was documented.
All LCNB (excluding the ﬁrst one), lumpectomy, re-exci-
sions, mastectomies, sentinel node biopsies, and axillary
lymph node dissections were included in the analysis.
Furthermore the total number of days between ﬁrst LCNB
and ﬁnal removal of all tumorous tissue was calculated for
each patient. To assess whether the number of surgical
procedures differed between patients with in situ carci-
noma and invasive carcinoma, a subgroup analysis was
performed. Patients with pure invasive carcinoma were
compared with patients with invasive and in situ carcinoma
on ﬁnal histopathology. Patients younger than the median
age were compared with patients older than the median
age. The number of surgical procedures and total number
of days until all tumorous tissue was removed for both
groups were compared using the t-test for the nonnormal
distribution (Mann–Whitney U-test). The number of con-
versions to mastectomy for both groups was compared
using the chi-square test. The number of surgical proce-
dures after ﬁnal histopathology was compared using the
analysis of variance (ANOVA) and Bonferroni test. Dif-
ferences in number of surgical interventions between
younger or older than the median age were compared using
the chi-square test. p-Value\0.05 was considered to be
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version 12.0.
RESULTS
After evaluation of the 856 eligible patients, 833
patients with 841 tumors were included in this study [mean
age ± standard deviation (SD) 60.0 ± 9.9 years]. In 4
patients no data on the initial core biopsy were available, in
7 patients core biopsy revealed no malignancy, and in 12
patients no data on follow-up after the core biopsy were
available (Fig. 1). Pathology revealed 337 in situ carcino-
mas and 504 invasive carcinomas. The left breast was
affected in 416 patients (49%), the right breast in 408
patients (49%), 8 patients had breast cancer in both breasts
(1%), and in 17 patients (2%) the affected side was
unknown (Table 1). The histological biopsy results are
summarized in Table 1. The median histological tumor
size was 12 mm (range 1–82 mm).
The number of surgical procedures after LCNB ranged
from one to four procedures, with a median of one. The
initial surgery consisted of BCS for 589 tumors (70%) and
of mastectomy for 242 tumors (29%). For ten tumors (1%)
the initial surgery was unknown. After BCS, 158/589
tumors (27%) required a re-excision, consisting of 67/158
tumors (42%) of BCS and 91/158 tumors (58%) of mas-
tectomy. Twenty-one of these 158 tumors (13%) required
more than one re-excision (Fig. 2 and Table 2). Finally
106/589 (18%) re-excisions after initial BCS were con-
verted to a mastectomy. The median number of days from
the time of the LCNB until all tumorous tissue was
removed was 28.
Subgroup analysis showed that the median number of
interventions after LCNB in both groups was one and the
range was one to four interventions for the patients diag-
nosed with an in situ carcinoma and one to three for the
patients diagnosed with an invasive carcinoma. Patients
with an in situ carcinoma on LCNB initially underwent
856 patients with 
856 lesions 
833 patients with 
841 lesions 
Cobra / Cobra 2000 
Pa  tients with a malignanc  y on 
core biopsy and treated within
1 year after initial biopsy 
4 patients, no av  ailable data 
on initial core biopsy 
7 patients, no malignanc  y 
on initial core biopsy 
12 patients, no follo  w-up 
data   av  ailable after  
initial core biopsy 
FIG. 1 Flowchart patient inclusion
TABLE 1 Baseline characteristics
Baseline characteristics Frequency
Number of patients 833
Number of tumors 841
Median age (years) 60
Affected side
Left 416
Right 408
Unknown 17
Median tumor size (mm) 12
Median tumor size in situ on LCNB (range) 12 (1–80 mm)
Median tumor size invasive on LCNB (range) 12 (2–82 mm)
Histology (on LCNB)
In situ
DCIS 307
LCIS 3
Both 2
Invasive
Ductal 420
Lobular 69
Both 4
Other breast malignancy 29
Unclear 7
841 LCNB
1589 (70%) BCS
In situ: 233 (73%)
Invasive: 347 (70%)
2242 (29%) mastectomy
In situ: 90 (27%)
Invasive: 152 (30%)
167 (42%) BCS
In situ: 45 (46%)
Invasive: 22 (36%)
1 mastectomy
BCS = Breast Conserving Surgery
1Patients undergoing a second LCNB or FNAB are included
210 unknown surgery
0 BCS
91 (58%) mastectomy
In situ: 52 (54%)
Invasive: 39 (64%)
2 (10%) BCS
In situ: 2 (100%)
Invasive: 0
18 (90%) mastectomy
In situ: 16 (100%)
Invasive: 2 (100%)
FIG. 2 Flowchart surgical procedures (BCS = breast conserving
surgery)
2254 S. van Esser et al.signiﬁcantly more breast amputations (Fig. 2 and Table 2)
than patients with an invasive carcinoma: 157/337 (47%)
versus 193/504 (38%) (p = 0.01).The total number of re-
excisions was 116/337 (34%) for patients diagnosed with
an in situ carcinoma and 63/504 (13%) for patients diag-
nosed with an invasive carcinoma (p = 0.0001). The
number of conversions from BCS to mastectomy differed
signiﬁcantly between both groups: 66/241 (28%) in
patients with an in situ carcinoma versus 40/348 (11%) in
patients with an invasive carcinoma (p = 0.0001). The
difference in median number of days until all tumorous
tissue was removed signiﬁcantly differed as well: 25 days
for patients with an invasive carcinoma and 38 days for
patients with an in situ carcinoma (p = 0.0001).
Patients who showed invasive ductal carcinoma and
ductal carcinoma in situ on histopathological evaluation
after surgery had signiﬁcantly more surgical interventions
than patients with pure ductal carcinoma in situ
(p = 0.048) and patients with pure invasive ductal carci-
noma (p = 0.001). Next, patients who showed an invasive
lobular carcinoma and an in situ lobular carcinoma on ﬁnal
histopathological evaluation had signiﬁcantly more surgi-
cal interventions than patients with pure invasive lobular
carcinoma (p = 0.01) and patients with an invasive ductal
carcinoma (p = 0.03) (Table 3).
Patients who were younger than the median age
(60 years) had signiﬁcantly more surgical interventions
than the patients older or equal to the median age
(p = 0.021).
Finally in this study we found a 5-year survival of 93%
for the patients with an invasive carcinoma and 98% for
patients with an in situ carcinoma; the overall 5-year sur-
vival was 95%.
DISCUSSION
To the best of our knowledge this is the ﬁrst large study
that solely describes the surgical performance of patients
diagnosed with nonpalpable breast carcinoma. Our results
show that a total of 179 tumors of the 841 (22%) needed re-
excisions to completely remove all tumorous tissue. The
number of re-excisions was signiﬁcantly higher in patients
with an in situ carcinoma then in patients with an invasive
carcinoma: 34% versus 13% (p = 0.0001). The number of
conversions from BCS to mastectomy was 18%; this
number was signiﬁcantly higher in patients diagnosed with
an in situ carcinoma: 28% versus 11% in patients with an
invasive carcinoma (p = 0.0001). Patients with both an in
TABLE 2 Surgical procedures in both groups
Invasive
carcinoma,
n (%)
In situ
carcinoma,
n (%)
Total, n (%)
First procedure
Breast conserving 348
a (70) 241
b (72) 589 (70)
Mastectomy 152 (30) 90 (27) 242 (29)
Second procedure
Breast conserving 22 (36) 45 (47) 67 (42)
Mastectomy 39 (64) 52 (54) 91 (58)
Third procedure
Breast conserving 0 2 (11) 2 (10)
Mastectomy 2 16 (89) 18 (90)
Fourth procedure
Breast conserving 0 0 0
Mastectomy 0 1 1 (100)
Total number of:
Breast conserving 370 (73) 288 (85) 658 (65)
Mastectomy 193 (38) 159 (47) 352 (35)
Total number of conversions
from breast conserving
to mastectomy
40
c (11) 66
d (28) 106 (18)
a Four missing
b Six missing
c One missing
d Three missing
TABLE 3 Histopathological results after surgery
Diagnosis Median histopathological
tumor size (range)
Frequency (%) Mean number of
surgical interventions
Pure DCIS 20.00 (2–80 mm) 206 (24.5) 2.29
Pure invasive ductal carcinoma 12.00 (2–60 mm) 388 (46.1) 2.10
Invasive ductal carcinoma and DCIS 10.00 (1–40 mm) 121 (14.4) 2.45
Pure invasive lobular carcinoma 15.00 (3–82 mm) 50 (5.9) 2.14
Invasive lobular carcinoma and LCIS 6.00 (5–8 mm) 3 (0.4) 3.00
Invasive ductal carcinoma and invasive lobular carcinoma 11.00 (5–50 mm) 43 (5.1) 2.19
LCIS and DCIS 13.00 (5–20 mm) 8 (1) 2.25
Other 12.00 (3–50 mm) 22 (2.6) 2.00
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ﬁnal histopathology and patients with both an in situ lob-
ular carcinoma and an invasive lobular carcinoma had
signiﬁcantly more re-excisions than patients with pure
invasive or in situ carcinomas. Patients younger than
60 years had signiﬁcantly more re-excisions than patients
aged 60 years or older.
Kurniawan et al. described the surgical outcome of
patients with both palpable and nonpalpable breast carci-
noma. All patients were included by way of the
mammography screening program. The patients undergo-
ing an initial mastectomy were excluded from this study.
The percentage of initial mastectomies in this study was
9%, which is lower than the percentage of initial mastec-
tomies in our study. The number of irradical re-excisions in
patients with both ductal carcinoma in situ (DCIS) and
invasive ductal carcinoma was higher than in the patients
with pure DCIS or pure invasive ductal carcinoma, corre-
sponding with our ﬁndings.
Next, they describe 23% conversions from initial BCS to
mastectomy.
19 This percentage is higher than our overall
percentage of conversions. This can be explained by the
fact that all tumors were included in this study: palpable,
nonpalpable, and T1–4 tumors, and the lower number of
initial mastectomies. Our number of conversions to mas-
tectomy is higher in patients diagnosed with an in situ
carcinoma. Kurniawan et al. did not perform a subgroup
analysis on the number of conversions for patients diag-
nosed with an in situ carcinoma.
There are several factors inﬂuencing the decision of
performing a re-excision and the kind of surgery in (non-
palpable) breast cancer. Firstly, the deﬁnition of tumor-free
margins is subject to discussion. The deﬁnition of tumor-
free resection margins ranges from 1 to 5 mm.
13,20 In lit-
erature we found tumor-positive resection margins in 35–
42% in patients with T1–4 tumors.
13,21 Again the tumors
described in these studies were both palpable and nonpal-
pable and larger (T1–4) than the tumors we analyzed. In
these studies a tumor-free margin was deﬁned as[5m m
from the inked resection plain. The number of re-excisions
we describe in this study is lower than described in the
literature; possibly the fact that in our study a tumor-free
margin of[1 mm was considered adequate contributed to
the lower number of re-excisions. Furthermore, in this
study focal irradicality of the excised tumor was treated
with radiotherapy as is described in literature.
22
Secondly, the hooked wire placement is an important
part of the surgical accuracy and is probably inﬂuenced by
the experience of the radiologist. The hooked wire was
placed in a routine clinical setting by both experienced and
inexperienced radiologists. Wire-guided localization has
several known disadvantages, such as wire displacement
and the chance of a pneumothorax.
11 Currently other
localization techniques, including the promising radio-
guided occult lesion localization technique, are subjected
to intensive research.
23–26
Thirdly the experience of the surgeon performing the
BCS is an important factor inﬂuencing the number of
tumor-free margins. Dedicated breast surgeons obtain more
tumor-free margins and perform less initial mastectomies
than surgical residents or general surgeons.
27,28 As in this
study both general and dedicated breast surgeons per-
formed the BCS and mastectomies, possibly the number of
tumor-free margins was lower and the number of initial
mastectomies was higher than when only dedicated breast
surgeons participated.
28 The overall number of days until
all tumorous tissue was removed was 28 and differed sig-
niﬁcantly between in situ carcinomas and invasive
carcinomas: 25 versus 38 days (p = 0.0001). In a study
assessing differences in dedicated versus general surgeons
the median duration from diagnosis to operation was found
to be 5 weeks, which is similar to our data.
28
Finally, the kind of treatment is inﬂuenced by the
patient’s desire. Although it is well known and overall
accepted that the survival rates after breast-conserving
procedures and breast amputations are the same in patients
with small localized breast carcinomas, around 35% of the
patients when offered the choice still choose to undergo a
mastectomy.
29,30 This could be an explanation for the high
number of primary mastectomies.
Reliable preoperative imaging is important for excision
with tumor-free margins of the tumor, especially in non-
palpable cancer that has to be radiologically localized prior
to surgery. Mammography and ultrasound are the most
widespread imaging modalities for imaging of breast
tumors. Unfortunately these imaging modalities have lim-
itations. Although not recorded in this study, overall
mammography and ultrasound tend to underestimate the
true tumor size as assessed on histopathology. The corre-
lation improves in larger tumors.
31 The patients with an in
situ carcinoma scheduled for a BCS in this study under-
went signiﬁcantly more breast amputations than the
patients with an invasive carcinoma. Limited possibilities
to delineate the extent of in situ carcinoma with mam-
mography and ultrasound could have contributed to the
number of irradical excisions. Although current data on
magnetic resonance imaging (MRI) are mixed, it could be
more accurate in preoperative tumor size and distribution
assessment and possibly reduce the number of re-
excisions.
32–34
The difference in the number of days between patients
with an in situ carcinoma and patients with an invasive
carcinoma could also be explained by the fact that deter-
mining the extent of in situ carcinoma is difﬁcult.
The survival found in this study is comparable to current
literature.
35
2256 S. van Esser et al.In conclusion, in this study we showed that it is difﬁcult
to completely remove all tumorous tissue in one procedure.
A total of 42% of patients diagnosed with early-stage
nonpalpable breast cancer had a mastectomy. The treat-
ment of in situ carcinoma is signiﬁcantly more frequently
converted from BCS to mastectomy than of invasive car-
cinoma. Improvements in preoperative imaging and
surgical technique for nonpalpable breast carcinoma are
needed to decrease the number of mastectomies.
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